# A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

> **NCT02976779** · PHASE1 · COMPLETED · sponsor: **One World Cannabis Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Safety Study for Future Treatment of Psoriasis

## Interventions

- **DRUG:** OWC MGC cream
- **DRUG:** OWC Control Cream

## Key facts

- **NCT ID:** NCT02976779
- **Lead sponsor:** One World Cannabis Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-03
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-01-25
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976779, "A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02976779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*